In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Rates of Re-hemorrhage, Risk Factors, and Outcomes of Previously Ruptured Arteriovenous Malformations (AVMs)

    Final Number:
    120

    Authors:
    Justin M. Caplan MD; Wuyang Yang MD, MS; Tomas Garzon-Muvdi MD MS; Geoffrey P. Colby MD, PhD, FAANS; Alexander L. Coon MD; Rafael Jesus Tamargo MD; Judy Huang MD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: The annual hemorrhage rate of unruptured AVMs is well established. However, hemorrhage risk of a previously ruptured AVM is not well defined. In this study, we describe the rate of AVM re-hemorrhage as well as the risk factors and outcomes associated with AVM re-hemorrhage from an institutional cohort.

    Methods: We retrospectively reviewed AVM patients from our institution seen from 1990-2015. Patients with hemorrhagic presentation were stratified into 1) patients with subsequent re-hemorrhage prior to treatment and 2) patients without re-hemorrhage. Patient demographic, clinical and angiographic data was compared across study groups. Cumulative and annual re-rupture rates were determined using Kaplan-Meier survival analysis.

    Results: Of the 247 patients with hemorrhagic presentation, 29(11.7%) re-bled prior to treatment. There were no statistically significant differences between groups for age, gender, race, Spetzler-Martin grade, eloquence involvement, deep venous drainage, venous stenosis, AVM location, feeding artery aneurysms and intranidal aneurysms. AVM size was larger in the re-hemorrhage group (3.5cm+/-2.1 vs. 2.5cm+/-1.4,p=0.032). Multivariate analysis identified age(HR1.03[CI1.00-1.05],p=0.043), Hispanic race(HR5.94[CI1.34-26.45],p=0.019), AVM size(HR1.31[1.02-1.68],p=0.035) and venous stenosis(HR3.9[1.03-14.73],p=0.045) as risk factors for re-hemorrhage. Presence of a venous varix(HR0.04[CI0.00-0.37],p=0.005 and significant venous dilatation(HR0.27[0.09-0.80],p=0.018) decreased the risk of re-hemorrhage. The cumulative risk of rupture at 2, 4, 12, 26 and 52 weeks was 0.9%, 1.3%, 2%, 3.2% and 5.5% respectively. The annual rate of re-rupture decreased from 7.09%(year 1) to 2.89%(year 10). Outcomes (dichotomized as good((modified Rankin score (mRS) 0-2) or poor (mRS 3-6)) were significantly improved in the patients without re-hemorrhage(79.8%) compared to re-hemorrhage patients(58.6%)(p=0.010).

    Conclusions: The rate of re-rupture is low immediately following initial hemorrhage of an AVM, with increasing cumulative risk over time. Outcomes in patients are significantly improved if there is no re-hemorrhage. This study helps identify the rates and risk factors associated with AVM re-hemorrhage, such that timing of treatment of a ruptured AVM may be optimized.

    Patient Care: Our findings will improve decision-making for timing of treatment for AVM patients with hemorrhagic presentation

    Learning Objectives: By the conclusion of this session, participants should be able to: 1. Appreciate the risk of re-rupture after initial hemorrhage for AVMs 2. Identify critical risk factors that modify re-rupture risk in ruptured patients 3. Understand that rate of re-rupture is low immediately following initial hemorrhage and increases cumulatively over time.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy